These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 14998323)

  • 1. Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.
    Wang S; Folkes A; Chuckowree I; Cockcroft X; Sohal S; Miller W; Milton J; Wren SP; Vicker N; Depledge P; Scott J; Smith L; Jones H; Mistry P; Faint R; Thompson D; Cocks S
    J Med Chem; 2004 Mar; 47(6):1329-38. PubMed ID: 14998323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.
    Wang S; Wan NC; Harrison J; Miller W; Chuckowree I; Sohal S; Hancox TC; Baker S; Folkes A; Wilson F; Thompson D; Cocks S; Farmer H; Boyce A; Freathy C; Broadbridge J; Scott J; Depledge P; Faint R; Mistry P; Charlton P
    J Med Chem; 2004 Mar; 47(6):1339-50. PubMed ID: 14998324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein.
    Lee BD; Li Z; French KJ; Zhuang Y; Xia Z; Smith CD
    J Med Chem; 2004 Mar; 47(6):1413-22. PubMed ID: 14998330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
    Fang L; Zhang G; Li C; Zheng X; Zhu L; Xiao JJ; Szakacs G; Nadas J; Chan KK; Wang PG; Sun D
    J Med Chem; 2006 Feb; 49(3):932-41. PubMed ID: 16451059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.
    Menichincheri M; Albanese C; Alli C; Ballinari D; Bargiotti A; Caldarelli M; Ciavolella A; Cirla A; Colombo M; Colotta F; Croci V; D'Alessio R; D'Anello M; Ermoli A; Fiorentini F; Forte B; Galvani A; Giordano P; Isacchi A; Martina K; Molinari A; Moll JK; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pillan A; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Vianello P; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2010 Oct; 53(20):7296-315. PubMed ID: 20873740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
    Zhu X; Sui M; Fan W
    Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
    Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Synergistic effect of bromocriptine combining tumor necrosis factor-alpha on reversing multidrug resistance in a nude mouse model of liver neoplasm].
    Ding L; Chen XP; Zhang ZW; Wang H; Cao B; Wang ZH; Li CL
    Zhonghua Wai Ke Za Zhi; 2005 Oct; 43(19):1248-53. PubMed ID: 16271222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
    Kasibhatla S; Baichwal V; Cai SX; Roth B; Skvortsova I; Skvortsov S; Lukas P; English NM; Sirisoma N; Drewe J; Pervin A; Tseng B; Carlson RO; Pleiman CM
    Cancer Res; 2007 Jun; 67(12):5865-71. PubMed ID: 17575155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure based optimization of novel Akt inhibitors.
    Lippa B; Pan G; Corbett M; Li C; Kauffman GS; Pandit J; Robinson S; Wei L; Kozina E; Marr ES; Borzillo G; Knauth E; Barbacci-Tobin EG; Vincent P; Troutman M; Baker D; Rajamohan F; Kakar S; Clark T; Morris J
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3359-63. PubMed ID: 18456494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents.
    Zhang N; Ayral-Kaloustian S; Nguyen T; Hernandez R; Lucas J; Discafani C; Beyer C
    Bioorg Med Chem; 2009 Jan; 17(1):111-8. PubMed ID: 19041247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of pyrrolopyrimidine inhibitors of Akt.
    Blake JF; Kallan NC; Xiao D; Xu R; Bencsik JR; Skelton NJ; Spencer KL; Mitchell IS; Woessner RD; Gloor SL; Risom T; Gross SD; Martinson M; Morales TH; Vigers GP; Brandhuber BJ
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5607-12. PubMed ID: 20810279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topological model for the prediction of MRP1 inhibitory activity of pyrrolopyrimidines and templates derived from pyrrolopyrimidine.
    Lather V; Madan AK
    Bioorg Med Chem Lett; 2005 Nov; 15(22):4967-72. PubMed ID: 16168641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological evaluation, structure-activity relationships, and three-dimensional quantitative structure-activity relationship studies of dihydro-beta-agarofuran sesquiterpenes as modulators of P-glycoprotein-dependent multidrug resistance.
    Reyes CP; Muñoz-Martínez F; Torrecillas IR; Mendoza CR; Gamarro F; Bazzocchi IL; Núñez MJ; Pardo L; Castanys S; Campillo M; Jiménez IA
    J Med Chem; 2007 Oct; 50(20):4808-17. PubMed ID: 17850057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OC144-093, a novel P glycoprotein inhibitor for the enhancement of anti-epileptic therapy.
    Newman MJ; Dixon R; Toyonaga B
    Novartis Found Symp; 2002; 243():213-26; discussion 226-30, 231-5. PubMed ID: 11990779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
    Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model.
    Gao L; Chen L; Fei XH; Qiu HY; Zhou H; Wang JM
    Chin Med J (Engl); 2006 Jun; 119(11):911-8. PubMed ID: 16780770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
    Chen YB; Yan ML; Gong JP; Xia RP; Liu LX; Li N; Lu SC; Zhang JG; Zeng DB; Xie JG; Yang JY; Yan LN
    Chin Med J (Engl); 2007 Apr; 120(8):703-7. PubMed ID: 17517188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.